+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Is the Rise in Plasma Beta-2-Microglobulin Seen during Hemodialysis Meaningful?

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          β<sub>2</sub>-Microglobulin (β2M) plasma levels and levels of a second low-molecular-weight protein (myoglobin) were studied during a 2- to 4-hour sham dialysis period (no dialysate flow, no weight loss) and during a 4- to 5-hour hemodialysis (HD) with a Cuprophan® capillary dialyzer. While no rise of the β2M or myoglobin levels occurred during sham dialysis, a rise of 22.1 ± (SD)8.5% (β2M) or 19.9 ± 12.1% (myoglobin) was seen during regular HD. The increases of both molecules showed a significant correlation (r = 0.44; p < 0.03). Both rises could not be completely abolished using correction factors for hemoconcentration. The rises occurred irrespectively of the dialysate buffer. The results suggest that neither the Cuprophan membrane nor the extracorporeal circuit were responsible for the rise of both molecules during HD. It seems more likely that changes of the extracellular volume and extra- to intracellular water shifts are involved and account for the majority of the rise. However, the possibility of minor increase in the extracellular mass of β2M or myoglobin cannot be excluded completely.

          Related collections

          Author and article information

          S. Karger AG
          09 December 2008
          : 51
          : 1
          : 6-12
          aDepartment of Nephrology, Hannover Medical School, FRG; bUniversity Hospital, Nîmes, France; cDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Mass., USA
          185232 Nephron 1989;51:6–12
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper

          Cardiovascular Medicine, Nephrology

          Hemodialysis, Myoglobin, Cellulosic membranes, β2-Microglobulin


          Comment on this article